Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 50, Issue 11, 2011, Pages 1120-1128

  Subramaniam, Geetha A ^a,b   Warden, Diane ^c   Minhajuddin, Abu ^c   Fishman, Marc J ^b,h   Stitzer, Maxine L ^b   Adinoff, Bryon ^c,g   Trivedi, Madhukar ^c   Weiss, Roger ^d   Potter, Jennifer ^e   Poole, Sabrina A ^f   Woody, George E ^f  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MCLEAN HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Veterans Affains North Texas Health Care System   (United States)

^h Mountain Manor Treatment Center   (United States)

Author keywords

buprenorphine treatment; opioid dependent youth; treatment predictors

Indexed keywords

AMPHETAMINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; COCAINE; LIVER ENZYME; OPIATE;

ADOLESCENT; ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ABUSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TOBACCO; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINALYSIS; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; BUPRENORPHINE; COMBINED MODALITY THERAPY; COUNSELING; FEMALE; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 80054865972     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2011.07.010     Document Type: Article

References (35)

1. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2009. Publication No. 10-7583. Bethesda, MD: National Institute on Drug Abuse; 2010.
2. Subramaniam GA, Stitzer MA, Woody GE, Fishman MJ, Kolodner K. Clinical characteristics of treatment-seeking adolescents with opioid versus cannabis/alcohol use disorders. Drug Alcohol Depend. 2009;99:141-149.
3. Subramaniam GA, Ives ML, Stitzer ML, Dennis ML. The added risk of opioid problem use among treatment-seeking youth with marijuana and/or alcohol problem use. Addiction. 2010;105:686-698.
4. DAWN. Detailed tables: national estimates, drug-related emergency department visits for 2004-2009. 2009. https://dawninfo. samhsa.gov/data//. Accessed February 1, 2011.
5. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2:CD002207.
6. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.
7. Parrino M. State Methadone Treatment Guidelines. TIPS Series 1.
8. DHHS Publication No. (SMA) 93-1991. Rockville, MD: Department of Health and Human Services; 1993.
9. Marsch LA, Bickel WK, Badger GJ et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62:1157-1164. (Pubitemid 41396941)
10. Woody GE, Poole SA, Subramaniam G et al. Extended vs shortterm buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300:2003-2011.
11. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006; 296:1286-1289. (Pubitemid 44394901)
12. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82:661-687. (Pubitemid 40143102)
13. Marsch LA, Stephens MA, Mudric T, Strain EC, Bigelow GE, Johnson RE. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol. 2005;13:293-302. (Pubitemid 43011154)
14. Gerra G, Borella F, Zaimovic A et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004;75:37-45. (Pubitemid 38844575)
15. Fiellin DA, Pantalon MV, Chawarski MC et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365-374. (Pubitemid 44127539)
16. Ziedonis DM, Amass L, Steinberg M et al. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend. 2009;99:28-36.
17. Torrington M, Domier CP, Hillhouse M, Ling W. Buprenorphine 101: treating opioid dependence with buprenorphine in an officebased setting. J Addict Dis. 2007;26:93-99. (Pubitemid 47367831)
18. Motamed M, Marsch LA, Solhkhah R, Bickel WK, Badger GJ. Differences in treatment outcomes between prescription opioiddependent and heroin-dependent adolescents. J Addict Med. 2008;2:158-164. doi:110.1097/ADM. 1090b1013e31816b31812f31884.
19. Mercer DE, Woody GE. An Individual Drug Counseling Approach to Treat Cocaine Addiction: The Collaborative Cocaine Treatment Study Model. NIH Publication No. 99-4380. Rockville, MD: National Institute of Drug Abuse; 1999.
20. Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Drug Alcohol Depend. 2010;107:253-256.
21. Meade CS, Weiss RD, Fitzmaurice GM et al. HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. J Acquir Immune Defic Syndr. 2010;55:65-72.
22. Miele GM, Carpenter KM, Smith Cockerham M, Dietz Trautman K, Blaine J, Hasin DS. Concurrent and predictive validity of the Substance Dependence Severity Scale (SDSS). Drug Alcohol Depend. 2000;59:77-88. (Pubitemid 30116840)
23. Needle R, Fisher DG, Weatherby N et al. Reliability of selfreported HIV risk behaviors of drug users. Psychol Addict Behav. 1995; 9:242-250. (Pubitemid 26019560)
24. NIDA. Risk Behavior Survey. 3rd ed. Rockville, MD: National Institute on Drug Abuse, Community Research Branch; 1993.
25. Achenbach TM. Manual for the YSR and 1991 Profile. Burlington, VT: Department of Psychiatry, University of Vermont; 1991.
26. Achenbach T. Manual for the Young Adult Self-Report and 1997 Profiles. Burlington, VT: Department of Psychiatry, University of Vermont; 1997.
27. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav. 1990;15:487-490. (Pubitemid 20333437)
28. SAS Institute. SAS, 9.2 Edition. Cary, NC: SAS Institute; 2010.
29. Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis. 2005;41:891-896. (Pubitemid 41266759)
30. Bachireddy C, Bazazi AR, Kavasery R, Govindasamy S, Kamarulzaman A, Altice FL. Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIVinfected prisoners in Malaysia: Implications for secondary prevention. Drug Alcohol Depend. 2011;116:151-157.
31. Hillhouse M, Domier CP, Chim D, Ling W. Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes. J Addict Dis. 2010;29:23-29.
32. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20:1038-1041.
33. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662-668. (Pubitemid 36246548)
34. Katz EC, Schwartz RP, King S et al. Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes. Am J Drug Alcohol Abuse. 2009;35:63-67.
35. Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend. 2006;83:218-224. (Pubitemid 44202249)